Additional inhibitors with improved selectivity and enhanced potency profiles need to be identified, and in vivo assessments using tools with adequate pharmacokinetic properties and target engagement need to be performed in order to further validate the anti-tumor efficacy of HPK1 inhibitors. The gene discussed is MAP4K1; the disease is neoplasm.